Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer
Heather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.
Dr. Han on the Importance of Risk Stratification in HER2+ Breast Cancer
Heather S. Han, MD, discusses the importance of risk stratification in HER2-positive breast cancer.
Dr. Han on the Importance of pCR in Breast Cancer
Heather S. Han, MD, discusses the importance of pathologic complete response in breast cancer.
Dr. Han on the Differences Between CDK 4/6 Inhibitors in ER+ Breast Cancer
Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512